000 | 01972 a2200613 4500 | ||
---|---|---|---|
005 | 20250515202347.0 | ||
264 | 0 | _c20100507 | |
008 | 201005s 0 0 eng d | ||
022 | _a1124-9390 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSozio, F | |
245 | 0 | 0 |
_aEfficacy and safety of a salvage regimen based on tipranavir, enfuvirtide and three nucleoside analogues in HIV1 infected patients with clinical progression: 96-week evaluation. _h[electronic resource] |
260 |
_bLe infezioni in medicina _cDec 2009 |
||
300 |
_a228-35 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Evaluation Study; Journal Article | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAlgorithms |
650 | 0 | 4 |
_aAnti-HIV Agents _xtherapeutic use |
650 | 0 | 4 | _aAntiretroviral Therapy, Highly Active |
650 | 0 | 4 | _aCD4 Lymphocyte Count |
650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
650 | 0 | 4 | _aDisease Progression |
650 | 0 | 4 | _aEnfuvirtide |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 | _aGenotype |
650 | 0 | 4 |
_aHIV Envelope Protein gp41 _xtherapeutic use |
650 | 0 | 4 |
_aHIV Fusion Inhibitors _xtherapeutic use |
650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
650 | 0 | 4 | _aHIV-1 |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aMutation |
650 | 0 | 4 |
_aPeptide Fragments _xtherapeutic use |
650 | 0 | 4 | _aPhenotype |
650 | 0 | 4 |
_aPyridines _xtherapeutic use |
650 | 0 | 4 |
_aPyrones _xtherapeutic use |
650 | 0 | 4 | _aSalvage Therapy |
650 | 0 | 4 | _aSulfonamides |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aPolilli, E | |
700 | 1 | _aD'Annunzio, Marco | |
700 | 1 | _aFalconi, L | |
700 | 1 | _aDi Masi, F | |
700 | 1 | _aTontodonati, M | |
700 | 1 | _aCosentino, L | |
700 | 1 | _aConsorte, A | |
700 | 1 | _aDi Giammartino, D | |
700 | 1 | _aParruti, G | |
773 | 0 |
_tLe infezioni in medicina _gvol. 17 _gno. 4 _gp. 228-35 |
|
999 |
_c19425662 _d19425662 |